Background
Histoplasma capsulatum is a dimorphic fungus that remains in a mycelial form at ambient temperatures and grows as yeast at body temperature in mammals. Infection causes histoplasmosis. Although the fungus that causes histoplasmosis can be found in temperate climates throughout the world, it is endemic to the Ohio, Missouri, and Mississippi River valleys in the United States. Internationally, the fungus is predominantly found in river valleys in North and Central America, eastern and southern Europe, and parts of Africa, eastern Asia, and Australia.
The soil in areas endemic for histoplasmosis provides an acidic damp environment with high organic content that is good for mycelial growth. Highly infectious soil is found near areas inhabited by bats and birds. Birds cannot be infected by the fungus and do not transmit the disease; however, bird excretions contaminate the soil, thereby enriching the growth medium for the mycelium. In contrast, bats can become infected, and they transmit histoplasmosis through droppings. Contaminated soil can be potentially infectious for years. Outbreaks of histoplasmosis have been associated with construction and renovation activities that disrupt contaminated soil. In addition, travelers to endemic areas are at risk for histoplasmosis because airborne spores can travel hundreds of feet.[1]
Most individuals with histoplasmosis are asymptomatic. Those who develop clinical manifestations are usually immunocompromised or are exposed to a high quantity of inoculum. Histoplasma species may remain latent in healed granulomas and recur, resulting in cell-mediated immunity impairment.
Pathophysiology
H capsulatum in the saprobic state grows in the mycelial form. Macroconidia and microconidia are produced on the hyphae of mycelium and are converted to the yeast form under temperature-controlled regulation. The aerosolization of conidia and mycelial fragments from contaminated soil results in alveolar deposition via inhalation.
The host defense includes the fungistatic properties of neutrophils and macrophages. T lymphocytes are crucial in limiting the extent of infection. Susceptibility to dissemination is increased markedly with impaired cellular host defenses.
Conversion from the mycelial to the pathogenic yeast form occurs intracellularly. After phagocytosis by macrophages, the yeast replicates in approximately 15-18 hours. Despite fusion with lysosomes, multiplication continues within the phagosomes. Proposed theories suggest that the yeasts may produce proteins that inhibit the activity of lysosomal proteases.
As the host immunity response develops, yeast growth ceases within 1-2 weeks after exposure. Cytokines systemically activate the fungistatic activity of macrophages against intracellular yeasts. With further maturation of the cell-mediated response, delayed-type hypersensitivity to histoplasmal antigens occurs (3-6 wk after exposure). Approximately 85-90% of individuals who are immunocompetent produce a positive response to skin antigen test for Histoplasma species.[2] Over weeks to months, the inflammatory response produces calcified fibrinous granulomas with areas of caseous necrosis.
Clinical manifestations of histoplasmosis appear with continued exposure to large inocula. The initial pulmonary infection may disseminate systemically, with hematogenous spread, and produce extrapulmonary manifestations. Hematogenous spread to regional lymph nodes may occur through the lymphatics or the liver and spleen. Progressive disseminated histoplasmosis is rare in adult hosts who are immunocompetent. Systemic spread usually occurs in patients with impaired cellular immunity and typically involves the CNS, liver, spleen, and rheumatologic, ocular, and hematologic systems.
Epidemiology
Frequency
United States
Histoplasmosis is the most common endemic fungal infection seen in humans. The central river valleys in the midwestern and south central United States are endemic for histoplasmosis. Approximately 250,000 individuals are infected annually. Clinical manifestations of histoplasmosis occur in less than 5% of the population. Most infections are sporadic, although large outbreaks of histoplasmosis may occur.
Population studies have demonstrated that greater than 80% of young adults from endemic areas (Ohio Valley, Mississippi Valley) have been previously infected with H capsulatum.[3]
International
The fungus is predominantly found in river valleys between latitudes 45° north and 30° south in South and Central America.[4]
Mortality/Morbidity
Morbidity and mortality are related to the duration and extent of systemic infection.
Approximately 90% of patients with acute pulmonary histoplasmosis are asymptomatic. Acute pericarditis can occur in as many as 5% of patients who are symptomatic.[1] The pericardial fluid is generally exudative.[4]Pleural effusions develop in 40-60% of patients with pericarditis.
Chronic pulmonary histoplasmosis occurs in patients with underlying lung disease. Patients develop cavities that may enlarge and result in necrosis. Untreated histoplasmosis may lead to progressive pulmonary fibrosis that results in respiratory and cardiac failure and recurrent infections.
Progressive disseminated histoplasmosis occurs in 1 case per 2000 cases in adults who are immunocompetent. Progressive disseminated histoplasmosis occurs in 4-27% of infected children, older individuals, persons who are immunosuppressed. In the subacute form, death occurs within 2-24 months in untreated cases. The acute form, if untreated, results in death within weeks.[3]
Sex
The rates of positive results on skin testing for sensitivity to antigens of H capsulatum are similar in males and females. Rheumatologic manifestations tend to occur predominantly in females.[5]
Age
Although histoplasmosis can affect individuals of any age, those in extreme age ranges are more prone to developing infection as a result of immature or deteriorated immune defenses.
Outbreak of histoplasmosis among travelers returning from El Salvador--Pennsylvania and Virginia, 2008. MMWR Morb Mortal Wkly Rep. Dec 19 2008;57(50):1349-53. [Medline].
Lowell JR. Diagnosis of histoplasmosis. Ann Intern Med. Feb 1983;98(2):260. [Medline].
Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. Jan 2007;20(1):115-32. [Medline].
Kauffman CA. Histoplasmosis. Clin Chest Med. Jun 2009;30(2):217-25, v. [Medline].
Hage CA, Wheat LJ, Loyd J, Allen SD, Blue D, Knox KS. Pulmonary histoplasmosis. Semin Respir Crit Care Med. Apr 2008;29(2):151-65. [Medline].
Picardi JL, Kauffman CA, Schwarz J, Holmes JC, Phair JP, Fowler NO. Pericarditis caused by Histoplasma capsulatum. Am J Cardiol. Jan 1976;37(1):82-8. [Medline].
Kamili QA, Menter A. Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol. Jan 2010;9(1):57-60. [Medline].
Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Joseph Wheat L. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis. Jan 1 2010;50(1):85-92. [Medline].
Freifeld AG, Wheat LJ, Kaul DR. Histoplasmosis in solid organ transplant recipients: early diagnosis and treatment. Curr Opin Organ Transplant. Dec 2009;14(6):601-5. [Medline].
Cuellar-Rodriguez J, Avery RK, Lard M, Budev M, Gordon SM, Shrestha NK. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis. Sep 1 2009;49(5):710-6. [Medline].
Wheat LJ. Improvements in diagnosis of histoplasmosis. Expert Opin Biol Ther. Nov 2006;6(11):1207-21. [Medline].
Corcoran GR, Al-Abdely H, Flanders CD, Geimer J, Patterson TF. Markedly elevated serum lactate dehydrogenase levels are a clue to the diagnosis of disseminated histoplasmosis in patients with AIDS. Clin Infect Dis. May 1997;24(5):942-4. [Medline].
Wheat LJ, Kohler RB, Tewari RP. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med. Jan 9 1986;314(2):83-8. [Medline].
Hage CA, Ribes JA, Wengenack NL, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis. Sep 2011;53(5):448-54. [Medline].
Davies SF, Rohrbach MS, Thelen V, et al. Elevated serum angiotensin-converting enzyme (SACE) activity in acute pulmonary histoplasmosis. Chest. Mar 1984;85(3):307-10. [Medline].
Hage CA, Davis TE, Fuller D, Egan L, Witt JR 3rd, Wheat LJ. Diagnosis of histoplasmosis by antigen detection in BAL fluid. Chest. Mar 2010;137(3):623-8. [Medline].
Hospenthal DR, Becker SJ. Update on Therapy for Histoplasmosis. Infect Med. April 13 2009;26:121-124.
[Guideline] Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807-825.
Bennish M, Radkowski MA, Ripon JW. Cavitation in acute histoplasmosis. Chest. Oct 1983;84(4):496-7. [Medline].
Davies SF, Khan M, Sarosi GA. Disseminated histoplasmosis in immunologically suppressed patients. Occurrence in a nonendemic area. Am J Med. Jan 1978;64(1):94-100. [Medline].
Freifeld A, Proia L, Andes D, Baddour LM, Blair J, Spellberg B. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother. Apr 2009;53(4):1648-51. [Medline].
Goldman M, Johnson PC, Sarosi GA. Fungal pneumonias. The endemic mycoses. Clin Chest Med. Sep 1999;20(3):507-19. [Medline].
Goodwin RA, Alcorn GL. Histoplasmosis with symptomatic lymphadenopathy. Chest. Feb 1980;77(2):213-5. [Medline].
Goodwin RA, Loyd JE, Des Prez RM. Histoplasmosis in normal hosts. Medicine (Baltimore). Jul 1981;60(4):231-66. [Medline].
Newman SL, Gootee L, Bucher C, Bullock WE. Inhibition of intracellular growth of Histoplasma capsulatum yeast cells by cytokine-activated human monocytes and macrophages. Infect Immun. Feb 1991;59(2):737-41. [Medline].
Paya CV, Roberts GD, Cockerill FR 3rd. Transient fungemia in acute pulmonary histoplasmosis: detection by new blood-culturing techniques. J Infect Dis. Aug 1987;156(2):313-5. [Medline].
Salzman SH, Schindel ML, Aranda CP, Smith RL, Lewis ML. The role of bronchoscopy in the diagnosis of pulmonary tuberculosis in patients at risk for HIV infection. Chest. Jul 1992;102(1):143-6. [Medline].
Salzman SH, Smith RL, Aranda CP. Histoplasmosis in patients at risk for the acquired immunodeficiency syndrome in a nonendemic setting. Chest. May 1988;93(5):916-21. [Medline].
Swartzentruber S, Rhodes L, Kurkjian K, Zahn M, Brandt ME, Connolly P. Diagnosis of acute pulmonary histoplasmosis by antigen detection. Clin Infect Dis. Dec 15 2009;49(12):1878-82. [Medline].
Wheat J. Histoplasmosis. Experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore). Sep 1997;76(5):339-54. [Medline].
Wheat J, Hafner R, Wulfsohn M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. Apr 15 1993;118(8):610-6. [Medline].
Wheat LJ. Systemic fungal infections: diagnosis and treatment. I. Histoplasmosis. Infect Dis Clin North Am. Dec 1988;2(4):841-59. [Medline].
Wheat LJ, Batteiger BE, Sathapatayavongs B. Histoplasma capsulatum infections of the central nervous system. A clinical review. Medicine (Baltimore). Jul 1990;69(4):244-60. [Medline].
Wheat LJ, Conces D, Allen SD, Blue-Hnidy D, Loyd J. Pulmonary histoplasmosis syndromes: recognition, diagnosis, and management. Semin Respir Crit Care Med. Apr 2004;25(2):129-44. [Medline].
Wheat LJ, Wass J, Norton J, Kohler RB, French ML. Cavitary histoplasmosis occurring during two large urban outbreaks. Analysis of clinical, epidemiologic, roentgenographic, and laboratory features. Medicine (Baltimore). Jul 1984;63(4):201-9. [Medline].

